Abstract:Background: Cancer vaccines that induce endogenous antitumor immunity represent an ideal strategy to overcome intractable cancers. However, doing this against a pre-established cancer using autologous immune cells has proven to be challenging. "Allogeneic effects" refers to the induction of an endogenous immune response upon adoptive transfer of allogeneic lymphocytes without utilizing hematopoietic stem cell transplantation. While allogeneic lymphocytes have a potent ability to activate host immunity as a cell adjuvant, novel strategies that can activate endogenous antitumor activity in cancer patients remain an unmet need. In this study, we established a new method to destroy pre-developed tumors and confer potent antitumor immunity in mice using alloantigen-activated CD4+ (named AAA-CD4+) T cells. Methods: AAA-CD4+ T cells were generated from CD4+ T cells isolated from BALB/c mice in cultures with dendritic cells (DCs) induced from C57BL/6 (B6) mice. In this culture, allogeneic CD4+ T cells that recognize and react to B6 mouse-derived alloantigens are preferentially activated. These AAA-CD4+ T cells were directly injected into the pre-established melanoma in B6 mice to assess their ability to elicit antitumor immunity in vivo. Results: Upon intratumoral injection, these AAA-CD4+ T cells underwent a dramatic expansion in the tumor and secreted high levels of IFN-γ and IL-2. This was accompanied by markedly increased infiltration of host-derived CD8+ T cells, CD4+ T cells, natural killer (NK) cells, DCs, and type-1 like macrophages. Selective depletion of host CD8+ T cells, rather than NK cells, abrogated this therapeutic effect. Thus, intratumoral administration of AAA-CD4+ T cells results in a robust endogenous CD8+ T cell response that destroys pre-established melanoma. This locally induced antitumor immunity elicited systemic protection to eliminate tumors at distal sites, persisted over 6 months in vivo, and protected the animals from tumor re-challenge. Notably, the injected AAA-CD4+ T cells disappeared within 7 days and caused no adverse reactions. Conclusions: Our findings indicate that AAA-CD4+ T cells reinvigorate endogenous cytotoxic T cells to eradicate pre-established melanoma and induce long-term protective antitumor immunity. This approach can be immediately applied to patients with advanced melanoma and may have broad implications in the treatment of other types of solid tumors.

Tumor Rejection Effects of Allorestricted Tumor Peptide-Specific CD4+T Cells on Human Cervical Cancer Cell Xenograft in Nude Mice

Allo-Restricted Ctls Generated By Coculturing Of Pbls And Autologous Monocytes Loaded With Allogeneic Peptide/Hla/Igg1-Fc Fusion Protein

Raising Allo-Restricted Cytotoxic T Lymphocytes by Co-Culture of Murine Splenocytes with Autologous Macrophage Bearing the Peptide/allo–major Histococompatibility Complex

A Modified HLA-A*0201-restricted CTL Epitope from Human Oncoprotein (hpebp4) Induces More Efficient Antitumor Responses

Specific Inhibition Of Tumor Growth By T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen Ny-Eso-1/Lage-1

In Vivo Anti-Melanoma Eycacy of Allo-Restricted CTLs Speciwc for Melanoma Expanded by Artiwcial Antigen-Presenting Cells

A Similarity in Peptide Cross-Reactivity Between Alloantigen- and Nominal Antigen-Induced CD8+ T Cell Responses in Vitro

Allogeneic Dendritic Cells Induce Potent Antitumor Immunity by Activating KLRG1+CD8 T Cells

Antigen-specific CD8+ Memory Stem T Cells Generated from Human Peripheral Blood Effectively Eradicate Allogeneic Targets in Mice

HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice

Alloantigen-activated (AAA) CD4+ T cells reinvigorate host endogenous T cell immunity to eliminate pre-established tumors in mice

Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells

CD4 + T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy

Semi-allogeneic Vaccine for T-cell Lymphoma

T-cell Receptor Gene Therapy Targeting Melanoma-Associated Antigen-A4 by Silencing of Endogenous TCR Inhibits Tumor Growth in Mice and Human

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice.

Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers

Tumor-specific T cells in head and neck cancer have rescuable functionality and can be identified through single-cell co-culture

Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.

Cervical Cancer-Associated Human Papillomavirus 16 E7 Oncoprotein Inhibits Induction of Anti-Cancer Immunity by a CD4+ T Cell Dependent Mechanism

Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells